It was approved for the first-line treatment of advanced NSCLC patients with EGFR-TKI-sensitive genetic mutations by the National Medical Products Administration (NMPA) of China in 2021 based on the AENEAS trial (Lu et al., 2022b). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.